clofarabine has been researched along with pf 00299804 in 1 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (pf 00299804) | Trials (pf 00299804) | Recent Studies (post-2010) (pf 00299804) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 180 | 41 | 172 |
| Protein | Taxonomy | clofarabine (IC50) | pf 00299804 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.037 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0392 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.094 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.11 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0006 | |
| Mitogen-activated protein kinase kinase kinase 8 | Homo sapiens (human) | 3.57 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 3.57 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0494 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
1 review(s) available for clofarabine and pf 00299804
| Article | Year |
|---|---|
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |